Impact of deploying multiple point-of-care tests with a ‘sample first’ approach on a sexual health clinical care pathway. A service evaluation

Objectives To assess clinical service value of STI point-of-care test (POCT) use in a ‘sample first’ clinical pathway (patients providing samples on arrival at clinic, before clinician consultation). Specific outcomes were: patient acceptability; whether a rapid nucleic acid amplification test (NAAT) for Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) could be used as a POCT in practice; feasibility of non-NAAT POCT implementation for Trichomonas vaginalis (TV) and bacterial vaginosis (BV); impact on patient diagnosis and treatment. Methods Service evaluation in a south London sexual health clinic. Symptomatic female and male patients and sexual contacts of CT/NG-positive individuals provided samples for diagnostic testing on clinic arrival, prior to clinical consultation. Tests included routine culture and microscopy; CT/NG (GeneXpert) NAAT; non-NAAT POCTs for TV and BV. Results All 70 (35 males, 35 females) patients approached participated. The ‘sample first’ pathway was acceptable, with >90% reporting they were happy to give samples on arrival and receive results in the same visit. Non-NAAT POCT results were available for all patients prior to leaving clinic; rapid CT/NG results were available for only 21.4% (15/70; 5 males, 10 females) of patients prior to leaving clinic. Known negative CT/NG results led to two females avoiding presumptive treatment, and one male receiving treatment directed at possible Mycoplasma genitalium infection causing non-gonococcal urethritis. Non-NAAT POCTs detected more positives than routine microscopy (TV 3 vs 2; BV 24 vs 7), resulting in more patients receiving treatment. Conclusions A ‘sample first’ clinical pathway to enable multiple POCT use was acceptable to patients and feasible in a busy sexual health clinic, but rapid CT/NG processing time was too long to enable POCT use. There is need for further development to improve test processing times to enable POC use of rapid NAATs.

[1]  R. Patel,et al.  ‘The waiting game’: are current chlamydia and gonorrhoea near-patient/point-of-care tests acceptable to service users and will they impact on treatment? , 2016, International journal of STD & AIDS.

[2]  J. Klausner,et al.  A Systematic Review of Point of Care Testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis , 2016, Infectious diseases in obstetrics and gynecology.

[3]  J. Schachter.  Point-of-care tests using enzyme detection to diagnose Chlamydia trachomatis infection do not work. But when they fail in clinical trials, they reappear under different names , 2016, Sexually Transmitted Infections.

[4]  Greg Ogrinc,et al.  Squire 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. , 2015, American journal of critical care : an official publication, American Association of Critical-Care Nurses.

[5]  A. Nardone,et al.  P65 Sexual behaviour in the time period between being tested for chlamydia and receiving test result and treatment , 2015, Sexually Transmitted Infections.

[6]  G. Brook.  The performance of non-NAAT point-of-care (POC) tests and rapid NAAT tests for chlamydia and gonorrhoea infections. An assessment of currently available assays , 2015, Sexually Transmitted Infections.

[7]  T. Nichols,et al.  Microscopy outperformed in a comparison of five methods for detecting Trichomonas vaginalis in symptomatic women , 2015, International journal of STD & AIDS.

[8]  N. Jahan,et al.  Comparison of four diagnostic techniques for detection of Trichomonas vaginalis infection in females attending tertiary care hospital of North India. , 2015, Indian journal of pathology & microbiology.

[9]  J. Kaldor,et al.  A field evaluation of a new molecular-based point-of-care test for chlamydia and gonorrhoea in remote Aboriginal health services in Australia. , 2015, Sexual health.

[10]  G. Whitlock,et al.  Diagnostics within the clinic to test for gonorrhoea and chlamydia reduces the time to treatment: a service evaluation , 2014, Sexually Transmitted Infections.

[11]  K. Turner,et al.  Mapping patient pathways and estimating resource use for point of care versus standard testing and treatment of chlamydia and gonorrhoea in genitourinary medicine clinics in the UK , 2014, BMJ Open.

[12]  Andrew St John,et al.  Existing and Emerging Technologies for Point-of-Care Testing. , 2014, The Clinical biochemist. Reviews.

[13]  Anne M Johnson,et al.  Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal) , 2013, The Lancet.

[14]  K. Turner,et al.  An early evaluation of clinical and economic costs and benefits of implementing point of care NAAT tests for Chlamydia trachomatis and Neisseria gonorrhoea in genitourinary medicine clinics in England , 2013, Sexually Transmitted Infections.

[15]  C. Gaydos,et al.  Performance of the Cepheid CT/NG Xpert Rapid PCR Test for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae , 2013, Journal of Clinical Microbiology.

[16]  C. Gaydos,et al.  Comparative effectiveness of a rapid point-of-care test for detection of Chlamydia trachomatis among women in a clinical setting , 2012, Sexually Transmitted Infections.

[17]  Nora L El-Tantawy,et al.  Performance of rapid immunochromatographic assay in the diagnosis of Trichomoniasis vaginalis. , 2012, Diagnostic microbiology and infectious disease.

[18]  E. Cromwell,et al.  Incremental Cost of Conducting Population-Based Prevalence Surveys for a Neglected Tropical Disease: The Example of Trachoma in 8 National Programs , 2011, PLoS neglected tropical diseases.

[19]  C. Marconi,et al.  Easiness of Use and Validity Testing of VS-SENSE Device for Detection of Abnormal Vaginal Flora and Bacterial Vaginosis , 2010, Infectious diseases in obstetrics and gynecology.

[20]  P. Nyirjesy,et al.  Use of the VS-sense swab in diagnosing vulvovaginitis. , 2009, Journal of women's health.

[21]  C. Black,et al.  The Natural History of Untreated Chlamydia trachomatis Infection in the Interval Between Screening and Returning for Treatment , 2008, Sexually transmitted diseases.

[22]  A. Sullivan,et al.  Texting decreases the time to treatment for genital Chlamydia trachomatis infection , 2006, Sexually Transmitted Infections.

[23]  E. Hook,et al.  The rapid test paradox: when fewer cases detected lead to more cases treated: a decision analysis of tests for Chlamydia trachomatis. , 1999, Sexually transmitted diseases.